title: Cymetra.
abstract: Soft tissue replacement using a filler as a temporary scaffold to encourage revascularization and tissue in growth is an exciting concept. Sheets of acellular human dermal matrix, called Alloderm (Lifecell Corp, Branchburg, NJ), have been shown to do just that. When implanted into a patient, tissue growth and revascularization have both been observed. The company manufactures a micronized or injectable form called Cymetra. This article reviews the manufacturing, tissue interaction, clinical applications, and anticipated clinical results.
authors.affiliation: The Maloney Center for Facial Plastic Surgery, Atlanta, Georgia, USA.
authors.forename: Brian P
authors.initials: BP
authors.lastname: Maloney
authors.forename: Brent A
authors.initials: BA
authors.lastname: Murphy
authors.forename: Harvey P
authors.initials: HP
authors.lastname: Cole
mesh_terms: D001672:Biocompatible Materials / Q000008:administration & dosage*; D003094:Collagen / Q000008:administration & dosage*; D005260:Female; D006085:Graft Survival; D006801:Humans; D007271:Injections, Intradermal / Q000379:methods; D007279:Injections, Subcutaneous / Q000379:methods; D008060:Lipodystrophy / Q000188:drug therapy; D008297:Male; D019736:Prostheses and Implants; D015361:Rhytidoplasty / Q000379:methods
chemical_list: D001672:Biocompatible Materials; C471832:Cymetra; D003094:Collagen